Claims for Patent: 9,211,332

Summary for Patent: 9,211,332

Title:	Selective resonance of bodily agents
Abstract:	Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.
Inventor(s):	Ishikawa; Muriel Y. (Livermore, CA), Jung; Edward K. Y. (Bellevue, WA), Leuthardt; Eric C. (St. Louis, MO), Myhrvold; Nathan P. (Medina, WA), Wood, Jr.; Lowell L. (Livermore, CA)
Assignee:	The Invention Science Fund I, LLC (Bellevue, WA)
Application Number:	13/457,993
Patent Claims:	1. A method, comprising identifying an agent in a body that modulates a biological activity in the body; selecting a set of noncontinuous differing energy inputs specific to the agent, wherein the set of differing energy inputs selectively resonates a plurality of resonant structures in the agent, including resonating at least one bond; and directing the set of differing energy inputs towards the agent while it is in the body, wherein directing the set of differing energy inputs towards the agent changes its modulation of the biological activity in the body. 2. The method of claim 1, wherein directing the set of differing energy inputs towards the agent initiates a therapeutic effect in the body. 3. The method of claim 1, wherein directing the set of differing energy inputs towards the agent terminates a therapeutic effect in the body. 4. The method of claim 1, wherein directing the set of differing energy inputs towards the agent destroys the agent. 5. The method of claim 1, wherein the agent is selected from the group consisting of analgesics, antacids, antianxiety drugs, antiarrhythmics, anticoagulants, anticonvulsants, antidepressants, antidiarrheals, antiemetics, antifungals, antihistamines, antihypertensives, anti-inflammatories, antiplatelet drugs, antipsychotics, antipyretics, antivirals, barbiturates, beta-blockers, bronchodilators, chemotherapy drugs, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, expectorants, hormones, hypoglycemics, immunosuppressives, laxatives, muscle relaxants, sedatives, sex hormones, sleeping drugs, tranquilizers, and vitamins. 6. The method of claim 5, wherein the agent is an antiplatelet drug. 7. The method of claim 6, wherein directing the set of differing energy inputs towards the agent destroys the agent. 8. The method of claim 7, wherein the agent is clopidogrel. 9. The method of claim 7, further comprising performing an incision on the body. 10. The method of claim 1, wherein the body is alive. 11. The method of claim 1, wherein the body is human. 12. The method of claim 1, wherein the agent is present in blood. 13. The method of claim 1, further comprising monitoring the body for activity of the agent. 14. The method of claim 1, further comprising monitoring the body for quantity of the agent. 15. The method of claim 1, wherein the agent comprises a functional group selected to be responsive to the set of differing energy inputs. 16. The method of claim 1, further comprising modifying the agent to add a functional group selected to be responsive to the set of differing energy inputs. 17. The method of claim 1, wherein the agent is selected from the group consisting of blood clotting factors, sugars, lipids, lipoproteins, vitamins, minerals, hormones, enzymes, antibodies, and proteins. 18. The method of claim 17, wherein the agent is a blood clotting factor selected from the group consisting of prekallikrein, high molecular weight kininogen, clotting factors I-XIII, von Willebrand factor, protein C, protein S, thrombomodulin, and antithrombin III. 19. The method of claim 17, wherein the agent is a sugar selected from the group consisting of glucose, fructose, sucrose, galactose, mannose, glycerol, and glucuronate. 20. The method of claim 17, wherein the agent is a lipid or lipoprotein selected from the group consisting of cholesterol, triglicerides, triacylglycerols, chylomicrons, very low density lipoproteins, low density lipoproteins, intermediate density lipoproteins, and high density lipoproteins. 21. The method of claim 17, wherein the agent is a hormone selected from the group consisting of adrenalin, adrenocorticotropic hormone, aldosteron, calcitonin, cortisol, insulin, gastrin, glucagon, glucocorticoids, thyroid hormone, gastrin, secretin, cholecystokinin, somatostatin, neuropeptide Y, other hormones of the gut, thyrotropin-releasing hormone, gonadotropin-releasing hormone, growth hormone-releasing hormone, ghrelin, corticotrophin-releasing hormone, somatostatin, dopamine, antidiuretic hormone, oxytocin, other hormones of the hypothalamus, renin, erythropoietin, calcitrol, other hormones of the kidney, insulin-like growth factor-1, angiotensinogen, thrombopoietin, other hormones of the liver, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin, growth hormone, adrenocorticotropic hormone, antidiuretic hormone, other hormones of the pituitary, estrogen, testosterone, progesterone, anabolic steroids, other reproductive hormones, melanocyte-stimulating hormone, parathyroid hormone, melatonin, prolactin, and thyroid hormones. 22. The method of claim 17, wherein the agent is an enzyme selected from the group consisting of creatine kinase, lactate dehydrogenase, troponin, other cardiac enzymes, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyltranspeptidase, and other liver enzymes. 23. The method of claim 17, wherein the agent is an antibody to an autoimmune disorders selected from the group consisting of acute transverse myelitis, allergic (Henoch-Schonlein) purpura, alopecia areata, aplastic anemia, brachial neuritis, bullous pemphigoid, dermatitis herpetiformis, polymyositis, dermatomyositis, Eaton-Lambert syndrome, eosinophilic fasciitis, Goodpasture's syndrome, Guillain-Barre syndrome, hemolytic anemia, hepatitis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus, peripheral ulcerative keratitis, polyglandular deficiency syndrome, relapsing polychondritis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and system lupus erythematosus. 24. The method of claim 17, wherein the agent is an antibody to a transplanted material. 25. The method of claim 24, wherein the transplanted material is selected from the group consisting of organs, stem cells, and device implants. 26. The method of claim 17, wherein the agent is a protein selected from the group consisting of albumins, globulins, fibrinogens, and hemoglobins.

Details for Patent 9,211,332

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2023-03-18